Digene Still Expecting HPV DNA Pap Test Primary Screen Approval By 2003
This article was originally published in The Gray Sheet
Executive Summary
Digene will re-analyze pivotal study data to demonstrate clinical utility of its HPV DNA Pap test as a primary screen for cervical cancer in response to an FDA request for additional information